Adenosine A(2a)-receptor activation increases contractility in isolated perfused hearts

Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1472-81. doi: 10.1152/ajpheart.2000.279.4.H1472.

Abstract

Adenosine A(2a)-receptor activation enhances shortening of isolated cardiomyocytes. In the present study the effect of A(2a)-receptor activation on the contractile performance of isolated rat hearts was investigated by recording left ventricular pressure (LVP) and the maximal rate of LVP development (+dP/dt(max)). With constant-pressure perfusion, adenosine caused concentration-dependent increases in LVP and +dP/dt(max), with detectable increases of 4.1 and 4.8% at 10(-6) M and maximal increases of 12.0 and 11.1% at 10(-4) M, respectively. The contractile responses were prevented by the A(2a)-receptor antagonists chlorostyryl-caffeine and aminofuryltriazolotriazinyl-aminoethylphenol (ZM-241385) but were not affected by the beta(1)-adrenergic antagonist atenolol. The adenosine A(1)-receptor antagonist dipropylcyclopentylxanthine and pertussis toxin potentiated the positive inotropic effects of adenosine. The A(2a)-receptor agonists ethylcarboxamidoadenosine and dimethoxyphenyl-methylphenylethyl-adenosine also enhanced contractility. With constant-flow perfusion, 10(-5) M adenosine increased LVP and +dP/dt(max) by 5.5 and 6.0%, respectively. In the presence of the coronary vasodilator hydralazine, adenosine increased LVP and +dP/dt(max) by 7.5 and 7.4%, respectively. Dipropylcyclopentylxanthine potentiated the adenosine contractile responses with constant-flow perfusion in the absence and presence of hydralazine. These increases in contractile performance were also antagonized by chlorostyryl-caffeine and ZM-241385. The results indicate that adenosine increases contractile performance via activation of A(2a) receptors in the intact heart independent of beta(1)-adrenergic receptor activation or changes in coronary flow.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine / analogs & derivatives*
  • Adenosine / pharmacology
  • Adenosine-5'-(N-ethylcarboxamide) / pharmacology
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Atenolol / pharmacology
  • Drug Synergism
  • Heart / drug effects
  • In Vitro Techniques
  • Male
  • Myocardial Contraction / drug effects
  • Myocardial Contraction / physiology*
  • Perfusion
  • Pertussis Toxin
  • Pressure
  • Purinergic P1 Receptor Agonists
  • Purinergic P1 Receptor Antagonists
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Adenosine A2A
  • Receptors, Purinergic P1 / physiology*
  • Vasodilation
  • Vasodilator Agents / pharmacology
  • Virulence Factors, Bordetella / pharmacology
  • Xanthines / pharmacology

Substances

  • Adrenergic beta-Antagonists
  • Purinergic P1 Receptor Agonists
  • Purinergic P1 Receptor Antagonists
  • Receptor, Adenosine A2A
  • Receptors, Purinergic P1
  • Vasodilator Agents
  • Virulence Factors, Bordetella
  • Xanthines
  • CGS 24012
  • Adenosine-5'-(N-ethylcarboxamide)
  • Atenolol
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Pertussis Toxin
  • Adenosine